316 related articles for article (PubMed ID: 17705288)
1. Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model.
Katsube T; Yamano Y; Yano Y
J Pharm Sci; 2008 Apr; 97(4):1606-14. PubMed ID: 17705288
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic-pharmacodynamic modeling and simulation for bactericidal effect in an in vitro dynamic model.
Katsube T; Yano Y; Yamano Y; Munekage T; Kuroda N; Takano M
J Pharm Sci; 2008 Sep; 97(9):4108-17. PubMed ID: 18314887
[TBL] [Abstract][Full Text] [Related]
3. Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysis.
Takata T; Aizawa K; Shimizu A; Sakakibara S; Watabe H; Totsuka K
J Infect Chemother; 2004 Apr; 10(2):76-85. PubMed ID: 15160299
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
Ong CT; Kuti JL; Nicolau DP;
Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program.
Kotapati S; Kuti JL; Nicolau DP
Surg Infect (Larchmt); 2005; 6(3):297-304. PubMed ID: 16201939
[TBL] [Abstract][Full Text] [Related]
6. Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa.
Shigemi A; Matsumoto K; Yaji K; Shimodozono Y; Takeda Y; Miyanohara H; Kawamura H; Orita M; Tokuda K; Nishi J; Yamada K
Int J Antimicrob Agents; 2009 Dec; 34(6):589-91. PubMed ID: 19748231
[TBL] [Abstract][Full Text] [Related]
7. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
Sumitani Y; Kobayashi Y
Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
[TBL] [Abstract][Full Text] [Related]
8. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
Goff DA; Nicolau DP
Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
Moczygemba LR; Frei CR; Burgess DS
Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
[TBL] [Abstract][Full Text] [Related]
10. [A comparison of susceptibility of Pseudomonas aeruginosa clinical isolates to carbapenem antibiotics in our hospital].
Kakeya H; Yamada K; Nakaie K; Takizawa E; Okada Y; Fujita A; Nakamura Y; Abe J; Hirose A; Kaneko Y; Hino M
Jpn J Antibiot; 2014 Aug; 67(4):241-8. PubMed ID: 25420320
[TBL] [Abstract][Full Text] [Related]
11. Dynamic interaction of colistin and meropenem on a WT and a resistant strain of Pseudomonas aeruginosa as quantified in a PK/PD model.
Mohamed AF; Kristoffersson AN; Karvanen M; Nielsen EI; Cars O; Friberg LE
J Antimicrob Chemother; 2016 May; 71(5):1279-90. PubMed ID: 26850719
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic/pharmacodynamic modeling and simulation to determine effective dosage regimens for doripenem.
Katsube T; Yano Y; Wajima T; Yamano Y; Takano M
J Pharm Sci; 2010 May; 99(5):2483-91. PubMed ID: 19904828
[TBL] [Abstract][Full Text] [Related]
13. [Rapid bactericidal activities of carbapenems against Pseudomonas aeruginosa in simulating human plasma concentrations].
Ishii C; Kakuta M; Abe T; Fukuoka T; Inoue M
Jpn J Antibiot; 2002 Apr; 55(2):187-95. PubMed ID: 12071096
[TBL] [Abstract][Full Text] [Related]
14. In Vitro Anaerobic Pharmacokinetic/Pharmacodynamic Model to Simulate the Bactericidal Activity of Levornidazole Against Bacteroides fragilis.
Hu J; Zhang J; Chen Y; Liang W; Wu S
Clin Ther; 2017 Apr; 39(4):828-836. PubMed ID: 28363695
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a pharmacokineticpharmacodynamic approach using software to optimize the carbapenem antibiotic regimen.
Ishihara N; Nishimura N; Tamaki H; Karino F; Miura K; Isobe T; Ikawa K; Morikawa N; Naora K
Int J Clin Pharmacol Ther; 2015 Jun; 53(6):422-9. PubMed ID: 25828635
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region.
Kiratisin P; Keel RA; Nicolau DP
Int J Antimicrob Agents; 2013 Jan; 41(1):47-51. PubMed ID: 23127484
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of antibiotics by the method of initial bactericidal activity].
Matsuda K; Inoue M
Jpn J Antibiot; 2000 Dec; 53(12):667-71. PubMed ID: 11234223
[TBL] [Abstract][Full Text] [Related]
18. In vivo pharmacodynamic activity of tomopenem (formerly CS-023) against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus in a murine thigh infection model.
Sugihara K; Sugihara C; Matsushita Y; Yamamura N; Uemori M; Tokumitsu A; Inoue H; Kakuta M; Namba E; Nasu H; Koga T
Antimicrob Agents Chemother; 2010 Dec; 54(12):5298-302. PubMed ID: 20921311
[TBL] [Abstract][Full Text] [Related]
19. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem.
Sakyo S; Tomita H; Tanimoto K; Fujimoto S; Ike Y
J Antibiot (Tokyo); 2006 Apr; 59(4):220-8. PubMed ID: 16830889
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region.
Roberts JA; Kwa A; Montakantikul P; Gomersall C; Kuti JL; Nicolau DP
Int J Antimicrob Agents; 2011 Mar; 37(3):225-9. PubMed ID: 21168997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
